Floatz logo

Empagliflozin

Chronic Kidney Disease(CKD)

Jinling Hospital, ChinaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Chronic Kidney Disease(CKD) cohort.

Asset / SponsorPhaseRating
SODIUM FERRIC GLUCONATE
Watson Pharmaceuticals
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Watson Pharmaceuticals
Phase 4BBB
Semaglutide
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB

View all 50 →

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →